Day: September 14, 2023

Crater Lake Scandium-Rare Earth Property, Aeromag with Mineralized Surface ShowingsYellow line outlines Globex claims.ROUYN-NORANDA, Quebec, Sept. 14, 2023 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to provide an update on Globex’s 100% owned Crater Lake Scandium property located 200km east of Schefferville, Quebec. Globex holds half the circular geological structure that contains the scandium-rare earth deposit held by Imperial Mining (“Imperial”). Today, Imperial announced that recent drilling has enabled them to increase their mineral resources estimate by 58% in total scandium tonnage...

CONCORD, NC, Sept. 14, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Hydromer Inc. (OTC: HYDI) (“The Company”), a worldwide supplier of specialty coatings and biopolymers for medical devices and industrial applications, announced today the release of a letter to shareholders from its Executive Chairman, Mr. Braeden Lichti. This letter, which is available for viewing at 2023-002.pdf (hydromer.com), offers an overview of the company’s current state. It elucidates both the achievements and challenges faced by the company, presents key highlights and recent updates, and outlines our strategic vision for the future. About Hydromer, Inc. Hydromer® has been a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 40 years. As a trusted partner to large and small...

Category 1 recovery Mexico City, Sept. 14, 2023 (GLOBE NEWSWIRE) — Grupo Aeromexico recognizes the great effort made by the authorities of the Secretariat of Infrastructure, Communications, and Transportation (SICT); the Ministry of Foreign Affairs (SRE); the Chambers of Deputies and Senators, as well as the Federal Civil Aviation Agency (AFAC), to achieve the necessary adjustments that today allow us to recover the Category 1 in civil aviation, by the Federal Aviation Administration of the United States (FAA). Aeromexico’s main objective is to continue connecting Mexico to the world. The return to Category 1 status allows us to strengthen connectivity with one of the country’s most important markets, the United States, to make more efficient use of the aircraft that have joined our fleet and to improve our customers’...

IMAGE: HEINEKEN MexicoYucatan, Mexico. The home of a new star.The company is committed to constructing a state-of-the-art brewery in Yucatán. The new brewery will set the standard for sustainable brewing, with focus on improved water processes and integrating circular economy practices. HEINEKEN Mexico expects to create over 2,000 new direct and indirect job opportunities.Amsterdam, 14 September 2023 – HEINEKEN Mexico plans to invest EUR 430 million in the establishment of a groundbreaking new brewery in Yucatán, with the ambition to expand sustainable brewing practices and foster community growth. This announcement was made in the presence of Raquel Buenrostro, Secretary of Economy of Mexico and Mauricio Vila Dosal, Constitutional Governor of Yucatán, alongside Guillaume Duverdier, Managing Director of HEINEKEN Mexico. Construction...

Ghent, 14 September 2023 – 6:30 p.m. – Press Release/Regulatory Information Highlights first half of 2023ABO-Group continues on its growth path and sees its total sales rise by another 10% to 40.4 million euros, amongst others due to strong organic growth of 14% in Belgium and the integration of the recent acquisitions of SEGED and DynaOpt in France Operating margins and net result were under pressure due to challenging (construction) market conditions in both France and the Netherlands, as well as the impact of rising interest rates Robust debt and solvency ratios provide a strong basis for further expansion of the acitvitiesOutlookWell-filled order book for the second half of the year – further development of the European mining sector expected to support geotechnical activities Integration of the two French and two Belgian acquisitions...

    Spineway organizes an international masterclasswith expert spine surgeons Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO1 (Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held on September 9 in Behoust (France) and focused on total disc replacement using prostheses. The event featured some 20 scientific papers and interactive round-table discussions led by opinion-leading surgeons who discussed their respective working practices and philosophies, and their experience with the prostheses used around the world and available...

–   Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion and recommended the approval of TransCon PTH (palopegteriparatide) as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. The European Commission’s final decision on the Company’s Marketing Authorisation Application is expected within 67 days after the positive opinion. TransCon PTH is a prodrug of parathyroid hormone (PTH [1-34]) administered once daily. “We are pleased to...

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of strokeClinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024 Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028Paris, France, September 14, 2023 – 5.45 pm CEST – Acticor Biotech, (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today its optimised development plan for Acute Ischemic Stroke (AIS) to register glenzocimab in Europe and the United States. ACTISAVE (NCT05070260) is an international phase 2/3 study, adaptive, multicentre, randomised, double-blind, placebo-controlled, parallel-group...